| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Biologics | Rare Diseases | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Biologics | Rare Diseases | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Biologics | Rare Diseases |
Recent Updates
Recently added Catalysts
AnaptysBio, Inc.$53.61
-0.54 (-1%)
C 43Pipeline Score Richly Valued Biotech · Clinical
Market Cap
1.49 B
EPS
-0.86
P/E Ratio
-59.9 $
Value Trade
47.68 M
SEC Financials
Q1 2026Dilution Risk
Revenue
25.56 M
R&D Expenses
33.99 M
Operating CF
-25.92 M
Total Assets
329.68 M
Total Liabilities
329.68 M
Equity
12.75 M
D/E Ratio
12,345
-3.99 %
Week
15.81 %
1 Month
62.96 %
3 Month
168.4 %
6 Month
255.05 %
5 Year
459.86 %
All Time
Cash Data
Cash Position
286.45 M
Monthly Burn
8.64 M
Runway
30.7 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
386.11 K
52 Week Range
11.40 - 72.36
% held by Insiders
6.26 %
% held by Institutions
97.75 %
Enterprise Value
1.48 B
Total Shares
29.30 M
Short %
18.02 %
Float Shares
17.26 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for AnaptysBio, Inc.
378Total events
10Upcoming
145Tier-1 (high impact)
2016 – 2028Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 2
TBD
◆IP Litigation RulingIP / Competition
Subscribe to view catalyst details
TBD
◆IP Litigation RulingIP / Competition
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-10-14 | ANB033 (CD122 antagonist) | phase 1b data readout | Phase 1b | — | – | – | – |
2025-10-14 | ANB033 (CD122 antagonist) | phase 1b data readout | Phase 1b | — | – | – | – |
2025-10-14 | ANB033 (CD122 antagonist) | phase 1b data readout | Phase 1b | — | – | – | – |
Drug Pipeline Intelligence
C43
Pipeline Score $226M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.2x
rNPV / MCap Top 67%
Micro Cap (rank 302 of 913)
Percentile RankAnaptysBio, Inc. carries a moderate pipeline score (43/100), with $566M risk-adjusted pipeline value, led by Etokimab in Atopic Dermatitis (Phase 2), across $95B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Etokimab Monoclonal antibody | Atopic Dermatitis | Phase 2 | NCT03533751 | 26% | $361M | COMPLETED | 302 | - | - | Dec 3, 2019 | - | May 24, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
rosnilimab | moderate-to-severe ulcerative colitis | Phase 2 | 2025-11-10 | clinical remission 400mg Q4W: 7%; clinical remission 800mg Q2W: 7%; endoscopic remission 400mg Q4W: 5%; endoscopic remission 800mg Q2W: 4%; baseline mean m MS score: 6.7; adverse events: >5% Read More | Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis Read More | |
rosnilimab | moderate-to-severe ulcerative colitis | Phase 2 | 2025-11-10 | clinical remission 400mg Q4W: 7%; clinical remission 800mg Q2W: 7%; endoscopic remission 400mg Q4W: 5%; endoscopic remission 800mg Q2W: 4%; baseline mean m MS score: 6.7; adverse events: >5% Read More | Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis Read More | |
rosnilimab | moderate-to-severe ulcerative colitis | Phase 2 | 2025-11-10 | clinical remission 400mg Q4W: 7%; clinical remission 800mg Q2W: 7%; endoscopic remission 400mg Q4W: 5%; endoscopic remission 800mg Q2W: 4%; baseline mean m MS score: 6.7; adverse events: >5% Read More | Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ANAB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ANAB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ANABAnaptys Announces First Quarter 2026 Financial Results and Provides Business Update
AnaptysBio reported its financial results for Q1 2026, highlighting a successful spin-off of First Tracks Biotherapeutics and strong sales growth for Jemperli. The company appointed Chris Murphy as CFO and added two experienced members to its Board of Directors. Despite a net loss increase, the company aims to protect its royalty streams and deliver value to shareholders.
Read more →ANABAnaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
AnaptysBio has appointed Christopher Murphy as Chief Financial Officer and Owen Hughes to its Board of Directors. These appointments aim to enhance the company's leadership team with expertise in finance, business development, and royalty management. The CEO expressed confidence that these additions will help protect and enhance shareholder value.
Read more →ANABAnaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
AnaptysBio, Inc. will have its CEO, Daniel Faga, participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on May 6, 2026. The discussion aims to highlight the company's financial collaborations, particularly with GSK and Vanda. This event is an opportunity for investors to gain insights into AnaptysBio's strategies and future directions.
Read more →ANAB▲ +14.8%on this news· ran to +30% by day 1
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
The Delaware Chancery Court has dismissed Tesaro's anticipatory breach claim against AnaptysBio, affirming Anaptys' position on the Collaboration Agreement. This ruling preserves the current royalty rates and sets a trial date for July 2026 to address Anaptys' contract claims against Tesaro and GSK. Anaptys is confident in its legal stance and aims to protect its interests in the Jemperli royalty stream.
Read more →ANAB▼ -24.5%on this news
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
AnaptysBio has completed the spin-off of First Tracks Biotherapeutics, transitioning to a focus on managing royalties from Jemperli and imsidolimab. The company will operate under a virtual model with minimal expenses and aims for a high EBIT margin. This strategic shift is designed to enhance shareholder value while navigating inherent risks associated with financial collaborations.
Read more →ANABFirst Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
AnaptysBio announced a $145 million private placement for its spin-off, First Tracks Biotherapeutics. The placement involves the sale of nearly 5.8 million shares at $13.81 each, expected to close upon the completion of the spin-off on April 20, 2026. Proceeds will be used for general corporate purposes, including clinical development of ANB033.
Read more →ANABAnaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
AnaptysBio, Inc. has announced a $100 million stock repurchase plan authorized by its Board of Directors. This decision follows the upcoming spin-off of First Tracks Biotherapeutics, which is set for April 20, 2026. The company aims to manage financial collaborations effectively while minimizing operating expenses. Additionally, Susannah Gray has been appointed to the Board, bringing valuable expertise to the company.
Read more →ANABAnaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
AnaptysBio, Inc. has approved the spin-off of First Tracks Biotherapeutics, which will begin trading on Nasdaq under the ticker TRAX on April 20, 2026. First Tracks Bio aims to develop next-generation antibody therapeutics for autoimmune diseases, with three lead candidates in various clinical trial phases. This strategic separation is intended to enhance focus and value for both companies.
Read more →ANAB▲ +14.6%on this news
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
AnaptysBio, Inc. announced plans to spin-off its biopharma operations into a new public company, First Tracks Biotherapeutics, aiming to enhance investor value. The company reported strong financial results for Q4 and the full year 2025, highlighting the promising potential of its pipeline assets, including ANB033, currently in Phase 1b trials. However, the separation process carries inherent risks and uncertainties.
Read more →ANAB▲ +5.2%on this news
Anaptys Announces $100 Million Stock Repurchase Plan
AnaptysBio, Inc. has announced a $100 million stock repurchase plan, expanding its existing program. The company expects to end 2025 with around $300 million in cash, bolstered by a potential $75 million milestone from GSK. The repurchase plan will run until March 31, 2026, but may be adjusted based on market conditions.
Read more →ANAB▲ +5.2%on this newsshared move
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
AnaptysBio has filed a Verified Complaint against Tesaro, alleging breach of their Collaboration Agreement and tortious interference by GSK. The lawsuit seeks a court declaration affirming Anaptys' rights under the agreement. This follows a history of disputes between the companies, including a previous settlement. The trial is expected in July 2026.
Read more →ANAB▼ -14.3%on this news
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
AnaptysBio announced that its Phase 2 trial of rosnilimab for moderate-to-severe ulcerative colitis failed to meet its primary and secondary endpoints at Week 12. Despite being safe and well tolerated, the drug showed inadequate efficacy, leading to the trial's discontinuation. The company will save at least $10 million as a result. Anaptys remains optimistic about rosnilimab's potential in rheumatoid arthritis and plans to update on its progress in H1 2026.
Read more →ANABAnaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
AnaptysBio reported its third quarter 2025 financial results, highlighting a significant increase in Jemperli sales and the strategic intent to separate its biopharma programs from royalty assets. The company is optimistic about its pipeline, particularly rosnilimab, which has shown promising Phase 2b data. The separation aims to align investment strategies with distinct asset values.
Read more →ANABAnaptys Announces Participation in November Investor Conferences
AnaptysBio, Inc. has announced its participation in several upcoming investor conferences, including the TD Cowen Immunology & Inflammation Summit and the Guggenheim Healthcare Innovation Conference. CEO Daniel Faga and other executives will represent the company at these events. Webcasts of the presentations will be available for 30 days post-conference, promoting transparency and investor engagement.
Read more →ANABAnaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
AnaptysBio announced positive results from its Phase 2b trial of rosnilimab for rheumatoid arthritis at ACR 2025. The trial, involving 424 patients, showed significant improvements in multiple response measures at Week 12, with benefits continuing through Week 28. Rosnilimab was well-tolerated, with no serious adverse events reported.
Read more →ANABAnaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
AnaptysBio announced that complete Phase 2b data for rosnilimab in rheumatoid arthritis will be presented at ACR Convergence 2025. The data highlights the drug's strong safety profile and durable efficacy. The presentation will be delivered by Professor Paul Emery, emphasizing the potential of rosnilimab as a treatment. AnaptysBio continues to focus on innovative immunology therapeutics.
Read more →ANAB▲ +31.6%on this news
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
AnaptysBio, Inc. will host a virtual investor event on October 14 to discuss ANB033, a CD122 antagonist. The event will feature Dr. Joseph A. Murray from the Mayo Clinic and will include a Q&A session. ANB033 is currently being studied in a Phase 1b trial for celiac disease. AnaptysBio is focused on innovative immunology therapeutics.
Read more →ANAB▲ +31.6%on this news
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
AnaptysBio plans to separate its operations into two independent companies, Royalty Management Co and Biopharma Co, by year-end 2026. This strategic move aims to enhance investor value by allowing alignment with different business models. The Biopharma Co will focus on developing innovative therapeutics, while Royalty Management Co will manage royalty assets from collaborations with GSK and Vanda Pharmaceuticals.
Read more →ANAB▼ -9.6%on this news
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
AnaptysBio announced positive results from its Phase 2b trial of rosnilimab for rheumatoid arthritis, demonstrating significant efficacy and safety. The trial involved 424 patients and showed that rosnilimab achieved low disease activity and remission over six months. The treatment was well tolerated, with durable responses observed even after discontinuation.
Read more →ANABAnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
AnaptysBio has appointed John Orwin as the new chairman of its Board of Directors, following Jamie Topper's resignation after more than 15 years. Orwin, with over 25 years in the biopharmaceutical sector, will provide guidance in drug development and corporate strategy as the company focuses on immune cell modulating therapies. Under Topper's leadership, AnaptysBio has evolved significantly, and he will remain an advisor until Q1 2024. The company is advancing multiple clinical-stage immune modulators targeting autoimmune and inflammatory diseases.
Read more →ANABAnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
AnaptysBio, Inc. announced that its CEO Daniel Faga and CMO Dr. Paul Lizzul will present at the upcoming Stifel 2023 Immunology and Inflammation Virtual Summit on September 19, 2023. The company focuses on developing innovative immunology therapeutics, including two checkpoint agonists currently in clinical trials for rheumatoid arthritis and atopic dermatitis. AnaptysBio is also evaluating several licensing opportunities for its products, though forward-looking statements highlight potential risks and uncertainties in achieving these goals.
Read more →ANABAnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
AnaptysBio, Inc. reported its second-quarter operating results, highlighting completion of enrollment in the GEMINI-1 Phase 3 trial for imsidolimab, and plans for a global Phase 2b trial for rosnilimab in rheumatoid arthritis. The company’s cash position remains strong, with funds projected to last through the end of 2026. Daniel Faga has been appointed as the permanent CEO, further reinforcing the leadership team. However, the company reported a net loss and a decrease in cash reserves since the previous year-end.
Read more →ANAB▲ +15.1%on this news
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
AnaptysBio and GSK received FDA approval for JEMPERLI (dostarlimab-gxly) combined with chemotherapy for patients with dMMR/MSI-H advanced or recurrent endometrial cancer. This approval represents a significant advancement as JEMPERLI is the first front-line immuno-oncology treatment for this patient population. The approval was based on part of GSK's Phase 3 RUBY trial and offers a chance for AnaptysBio to receive royalties, which may support its future development projects. More data from GSK's ongoing studies are expected in 2024, which could expand JEMPERLI's indications.
Read more →ANABAnaptysBio Announces Participation in Upcoming Investor Conferences
AnaptysBio, Inc. has announced participation in two upcoming investor conferences, which may bolster its visibility among investors. The company, focused on immunology therapeutics, is currently developing several clinical-stage candidates, including rosnilimab for rheumatoid arthritis and ANB032 for atopic dermatitis. Risk factors include uncertainties related to advancing product candidates and the ability to secure regulatory approvals, which could impact the company's future performance. The presence of senior management at these conferences indicates efforts to strengthen investor relations.
Read more →ANABAnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
AnaptysBio reported its financial results for Q1 2023, highlighting progress in its clinical pipeline. The company has initiated a global Phase 2b trial for its BTLA agonist ANB032 targeting atopic dermatitis, alongside plans for a Phase 2b trial with rosnilimab for rheumatoid arthritis later this year. AnaptysBio also continues to emphasize its financial stability with an expected cash runway through 2026. However, the company reported a net loss increase compared to the previous year, raising concerns about rising operational costs.
Read more →ANABAnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
AnaptysBio published Phase 2 GALLOP data for imsidolimab, showing rapid and sustained efficacy in patients with generalized pustular psoriasis (GPP) after a single dose. The study indicated acceptable safety profiles, with low adverse event incidence. As the company prepares for top-line results from the ongoing GEMINI-1 Phase 3 trial expected in Q4 2023, they anticipate a potential licensing opportunity for imsidolimab. The drug has already received Orphan Drug Designation from the FDA due to its treatment relevance for GPP.
Read more →ANABAnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
AnaptysBio has announced the immediate appointment of Dr. Rita Jain, M.D., to its Board of Directors, a move that the company's interim CEO, Daniel Faga, endorses due to her extensive drug development expertise in rheumatology. Dr. Jain expressed enthusiasm for AnaptysBio's innovative immune cell modulating portfolio, particularly as the company advances drug candidates through clinical trials. Alongside this appointment, Laura J. Hamill has resigned from the Board after nearly four years of service, during which she contributed significantly to the company's strategic direction.
Read more →ANABAnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone in Phase 3 RUBY trial
AnaptysBio and GSK announced positive interim results from the Phase 3 RUBY trial, which investigated the immuno-oncology agent Jemperli (dostarlimab-gxly) combined with chemotherapy for treating primary advanced or recurrent endometrial cancer. The results showed a statistically significant and clinically meaningful improvement in progression-free survival compared to chemotherapy alone, particularly in patients with dMMR/MSI-H tumors. GSK plans to proceed with regulatory submissions for Jemperli in the first half of 2023, indicating strong commercial potential for both companies.
Read more →ANABAnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
AnaptysBio, Inc. reported its financial results for Q4 2022 and outlined significant business updates, including the initiation of global Phase 2b trials for two investigational therapies: rosnilimab for rheumatoid arthritis and ANB032 for atopic dermatitis. The company highlighted its strong financial position, with a cash runway projected through 2026, despite a decrease in overall liquidity compared to the previous year. Furthermore, AnaptysBio is advancing its portfolio of immune cell modulators while awaiting key data from ongoing trials, including the Phase 3 trial for imsidolimab aimed at generalized pustular psoriasis.
Read more →ANABAnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
AnaptysBio, a clinical-stage biotechnology company, will present at the Cowen and Company 43rd Annual Health Care Conference on March 6, 2023. Interim CEO Dan Faga will provide insights on the company's innovative immunology therapeutics, including developmental updates on their PD-1 and BTLA agonists. A live audio webcast will be conducted, with a replay available for at least 30 days post-event.
Read more →ANAB▲ +14.3%on this news
AnaptysBio Announces Stock Repurchase Plan
AnaptysBio, Inc. has announced a Stock Repurchase Plan allowing the repurchase of up to $50 million of its common stock. With a strong cash position exceeding $575 million as of the end of 2022, the company anticipates a capital runway of roughly four years for its research and development efforts. The plan may be executed through open market transactions and will expire on December 31, 2023, but does not obligate AnaptysBio to repurchase any set amount of stock. AnaptysBio continues to focus on developing innovative therapeutics for autoimmune and inflammatory diseases.
Read more →ANABAnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
AnaptysBio has announced advancements in its portfolio, specifically progressing rosnilimab and ANB032 into global Phase 2b trials targeting rheumatoid arthritis and atopic dermatitis, respectively. A blinded interim review of rosnilimab data for alopecia areata showed 'proof of mechanism,' but did not support continuing development due to unachieved efficacy goals. The firm has expressed confidence in its financial capabilities, expecting to maintain operations for the next four years with over $575 million in capital. Future developments and trial results are anticipated in the coming years.
Read more →ANABAnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with primary advanced or recurrent endometrial cancer First-in-class pivotal data in endometrial cancer, if approved, to be a potential
Read more →ANABAnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, interim chief executive officer of AnaptysBio, will represent the company
Read more →ANABAnaptysBio to Participate in Upcoming November Investor Conferences
SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer of AnaptysBio, will represent the company in a fir
Read more →ANABAnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
Anticipate Rosnilimab, our anti-PD-1 agonist antibody, top-line data in the ongoing AZURE Phase 2 trial in moderate-to-severe alopecia areata in Q1 2023 Anticipate ANB032, our anti-BTLA agonist antibody, U.S. IND submission for a Phase 2 trial in Q4 2022 Announced our third who
Read more →ANABAnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials
Positive headline results from PERLA, a head-to head Phase 2 trial of JEMPERLI vs. Keytruda in patients with metastatic non-squamous non-small cell lung cancer COSTAR, a Phase 2 trial of JEMPERLI plus cobolimab, an anti-TIM-3 antagonist antibody licensed to TESARO, Inc. (GSK) as
Read more →ANABAnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million
SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that the company has sold its royalty interest on future global net sales of Zejula to a
Read more →ANABAnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa
Imsidolimab (anti-IL-36 receptor antagonist) did not demonstrate improvement over placebo in the primary endpoint and key secondary endpoints Imsidolimab was safe and well tolerated with no imsidolimab-related serious or severe adverse events reported Company to discontinue ims
Read more →ANABAnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update
Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3 2022 Top-line data from the ongoing rosnilimab (anti-PD-1 agonist Ab) AZURE Phase 2 trial in moderate-to-severe alopecia areata is a
Read more →ANAB▲ +6.7%on this newsshared move
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference
SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of Anaptys
Read more →ANABAnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that
Read more →ANABAnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update
Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3 2022 Top-line data from the ongoing imsidolimab GEMINI-1 Phase 3 trial in GPP is anticipated in Q4 2023 Top-line data from the ongo
Read more →ANABAnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates
ANB032, our wholly owned anti-BTLA agonist antibody, demonstrated favorable safety, tolerability and a rapid and sustained pharmacokinetic and pharmacodynamic profile that supports advancement of ANB032 into subsequent patient trials ANB032 IND filing in an initial proof-of-conc
Read more →ANABAnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer
Company to undergo a strategic portfolio review while continuing to execute on the development of its three wholly-owned clinical stage antibody programs SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company develop
Read more →ANABAnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne
Imsidolimab (anti-IL-36R Ab) treatment did not demonstrate improvement over placebo in top-line primary or secondary endpoints AnaptysBio to discontinue imsidolimab clinical development in acne Imsidolimab was generally safe, well tolerated and no imsidolimab-related serious or
Read more →ANABAnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update
Imsidolimab GPP GALLOP Phase 2 16-week data presented at 2021 EADV Congress and Phase 3 GPP GEMINI-1 trial initiated Top-line data anticipated from ongoing imsidolimab ACORN Phase 2 trial in moderate-to-severe acne in H1 2022 and HARP Phase 2 trial in moderate-to-severe hidraden
Read more →ANAB▼ -6.9%on this news
AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, tod
Read more →ANABAnaptysBio Announces Appointment of Daniel Faga to Board of Directors
SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, tod
Read more →ANABAnaptysBio To Present at the 2021 Jefferies London Healthcare Conference
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, tod
Read more →ANABAnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
Rosnilimab, AnaptysBio’s wholly-owned anti-PD-1 agonist antibody, demonstrated favorable safety and tolerability in single and multiple ascending dose healthy volunteer cohorts Robust pharmacokinetic profile, in conjunction with rapid and sustained PD-1 receptor occupancy Pharm
Read more →ANABAnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates
Imsidolimab GPP GALLOP Phase 2 16-week data presented at 2021 EADV Congress and GEMINI-1 Phase 3 trial initiated subsequent to FDA end-of-Phase 2 meeting Top-line data from ongoing imsidolimab ACORN Phase 2 trial in moderate-to-severe acne anticipated in H1 2022 and HARP Phase 2
Read more →ANABAnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard
AnaptysBio to receive $250 million upfront cash payment from Sagard Healthcare Royalty Partners Sagard to receive AnaptysBio’s 8% royalty on annual global net sales of JEMPERLI (dostarlimab-gxly) below $1 billion, plus certain future regulatory and commercial sales milestones, w
Read more →ANABAnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis
Imsidolimab demonstrated rapid and sustained efficacy with 6 of 8 (75%) generalized pustular psoriasis (GPP) patients achieving the primary endpoint at week 4 and week 16 Early reduction of erythema with pustules by 60% at week 1 improved to 94% reduction at week 4 and 98% reduc
Read more →ANABAnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, to
Read more →ANABAnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates
Imsidolimab GPP GEMINI-1 Phase 3 trial anticipated to initiate in Q3 2021 following recent FDA end-of-Phase 2 Meeting Imsidolimab GALLOP GPP Phase 2 trial 16-week data to be orally presented at the EADV Congress on October 2nd, 2021 Imsidolimab Phase 2 trials ongoing in acne, h
Read more →ANABAnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference
SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, toda
Read more →ANABAnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates
Imsidolimab Phase 3 GPP trial anticipated to commence in mid-2021 following FDA end-of-Phase 2 meeting held during Q2 2021 JEMPERLI (dostarlimab), our PD-1 antagonist antibody partnered with GlaxoSmithKline (GSK), was approved for endometrial cancer in the US and EU during Q2 20
Read more →ANABAnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, to
Read more →ANABAnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint
Imsidolimab treatment did not demonstrate statistically significant improvement over placebo in PPPASI change from baseline at week 16 primary endpoint Imsidolimab was generally well tolerated and no serious or severe adverse events were reported in the drug arm of the trial An
Read more →ANABAnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates
Positive topline data from GALLOP Phase 2 clinical trial of imsidolimab in moderate to severe generalized pustular psoriasis (GPP) announced in October 2020, with Phase 3 trial initiation anticipated in mid-2021 Topline data from POPLAR Phase 2 imsidolimab clinical trial in palm
Read more →ANABAnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, tod
Read more →ANABAnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, tod
Read more →ANABAnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline Updates
Positive topline data from GALLOP Phase 2 clinical trial of imsidolimab in moderate to severe Generalized Pustular Psoriasis (GPP) announced in October 2020 FDA end-of-Phase 2 meeting anticipated in Q4 2020 to outline registration path of imsidolimab for the treatment of GPP, in
Read more →ANABAnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration
Dostarlimab royalties to AnaptysBio increase from 4-8% to 8-25% of global net sales, with first US approval in endometrial cancer anticipated in Q4 2020 Additional 1% royalty to AnaptysBio on GSK’s global net sales of Zejula™ (niraparib) starting January 2021 GSK to pay one-tim
Read more →ANABAnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)
6 of 8 patients achieved primary endpoint of improvement in the clinical global impression scale (CGI) on Day 29, with rapid reduction of skin pustules by 60% on Day 8 and 94% clearance on Day 29 FDA end-of-Phase 2 meeting anticipated in Q4 2020 to outline registration path of i
Read more →ANABAnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare Conference
SAN DIEGO, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of
Read more →ANABANAPTYSBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating AnaptysBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against AnaptysBio, Inc. (NASDAQ: ANAB) on behalf of long-term stockholders. Our investigation concerns whether the boa
Read more →ANABAnaptysBio Reports Top-Line Data from Interim Analysis of ECLIPSE Phase 2 Clinical Trial of Etokimab in Chronic Rhinosinusitis with Nasal Polyps
Etokimab q4w and q8w treatment arms failed to achieve NPS and SNOT-22 statistical significance over placebo at this week 8 interim analysis Secondary analyses demonstrated NPS and blood eosinophil level improvement in both asthma and non-asthma comorbid patients versus placebo i
Read more →ANABAnaptysBio Announces Second Quarter 2020 Financial Results and Provides Pipeline Updates
Interim 8-Week Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Did Not Demonstrate Statistical Significance For Either Q4W or Q8W Versus Placebo; Company Plans To Assess Path Forward for Etokimab After Complete 16-Week Trial Data by y
Read more →ANABAnaptysBio to Present at The 2020 Wedbush PacGrow Healthcare Conference
SAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of
Read more →ANABAnaptysBio Appoints Dr. Paul F. Lizzul As Chief Medical Officer
SAN DIEGO, July 31, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, tod
Read more →ANABAnaptysBio Expands Executive Leadership Team
SAN DIEGO, July 15, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, tod
Read more →ANABAnaptysBio Announces Orphan Drug Designation of Imsidolimab For Treatment of Generalized Pustular Psoriasis
Additional Data and Regulatory Strategy Update From Generalized Pustular Psoriasis (GPP) Phase 2 GALLOP Trial Anticipated During H2 2020 Palmoplantar pustulosis (PPP) Phase 2 POPLAR Trial Top-Line Data Anticipated in H2 2020 Company Plans To Expand Clinical Development of Imsid
Read more →ANABANAPTYSBIO DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In AnaptysBio, Inc. To Contact The Firm
NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. (“Anaptys” or the “Company”) (NASDAQ:ANAB) of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities class
Read more →ANABANAPTYSBIO LOSS ALERT: ROSEN, A TOP RANKED FIRM, Reminds AnaptysBio, Inc. Investors to Contact Firm Prior to May 26 Deadline for Class Action Seeking Recovery of Investor Losses – ANAB
NEW YORK, May 08, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”), of the important May 26, 2020 lead
Read more →ANABAnaptysBio Announces First Quarter 2020 Financial Results and Provides Pipeline Updates
Interim Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Anticipated in Third Quarter of 2020, Decided to Over-Enroll Trial Due to COVID-19 Additional Topline Data from GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-t
Read more →ANABANAPTYSBIO, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for Southern District of California against AnaptysBio, Inc.
NEW YORK and SAN DIEGO, April 01, 2020 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in United States District Court for Southern District of California on behalf of investors who purchased AnaptysBio, Inc. ("A
Read more →ANABAnaptysBio (ANAB) Class Action Alert: Johnson Fistel Encourages Investors to Contact Firm
SAN DIEGO, March 27, 2020 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of shareholders of AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB). The class action is on behalf of sharehol
Read more →ANABAnaptysBio Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Pipeline Updates
Interim Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Anticipated in First Half of 2020 Reported Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized P
Read more →ANABAnaptysBio to Present at The Cowen and Company 40th Annual Health Care Conference
SAN DIEGO, Feb. 25, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of
Read more →ANABANAPTYSBIO PRESENTATION Exhibit
ANAPTYSBIO PRESENTATION Exhibit
Read more →ANABAnaptysBio to Present at J.P. Morgan Annual Healthcare Conference
SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of
Read more →ANABAnaptysBio Announces Third Quarter 2019 Financial Results and Provides Pipeline Updates
Topline Data From Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Failed to Meet Primary Endpoint Reported Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular
Read more →ANABAnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Fails to Meet Primary Endpoint
SAN DIEGO, Nov. 08, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced topline data from its ATLAS trial, a Phase 2b
Read more →ANABAnaptysBio Reports Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis
Interim analysis conducted with first two patients to complete 16-week (Day 113) ANB019 monotherapy study Both patients achieved the primary endpoint of disease score improvement at Day 29 and Day 113 without requiring rescue therapy Patients demonstrated rapid and sustained mJ
Read more →ANABAnaptysBio to Present at the Cantor Fitzgerald Global Healthcare Conference
SAN DIEGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of
Read more →ANABAnaptysBio Announces Second Quarter 2019 Financial Results and Provides Pipeline Updates
Multiple Top-line Phase 2 Clinical Efficacy Readouts from Wholly-owned Pipeline Anticipated in 2019 Etokimab Phase 2b Eosinophilic Asthma Trial Initiation Anticipated in 4Q19 IND Filing for Company’s Third Wholly-Owned Program, ANB030, an anti-PD-1 Agonist, Expected in 4Q19 Re
Read more →ANABAnaptysBio to Present at the Wedbush PacGrow 2019 Healthcare Conference
SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of
Read more →ANABAnaptysBio Presents Updated Data from Etokimab Phase 2a Proof-of-Concept Clinical Trial in Severe Eosinophilic Asthma
Single dose of etokimab resulted in rapid and sustained lung function improvement and ACQ-5 score reduction through at least Day 64 Etokimab was well tolerated and no serious adverse events were reported Data supports infrequent dosing of etokimab in the treatment of eosinophil
Read more →ANABAnaptysBio to Present at the Jefferies 2019 Healthcare Conference
SAN DIEGO, May 28, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of A
Read more →ANABAnaptysBio Announces First Quarter 2019 Financial Results and Provides Pipeline Updates
Multiple Top-line Phase 2 Clinical Efficacy Readouts from Wholly-owned Pipeline Anticipated in 2019 Etokimab Phase 2a Severe Eosinophilic Asthma Data to be Presented at the 2019 EAACI Congress IND Filing for New Wholly-owned Anti-inflammatory Program Anticipated in Second Half
Read more →ANABAnaptysBio to Present at the Bank of America Merrill Lynch Healthcare Conference
SAN DIEGO, May 01, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of A
Read more →ANABAnaptysBio to Present at the Cowen and Company 39th Annual Health Care Conference
SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of
Read more →ANABAnaptysBio Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Pipeline Updates
Reported positive top-line data from an interim analysis of a Phase 2a proof-of-concept trial of etokimab in severe eosinophilic asthma Four top-line Phase 2 clinical efficacy readouts from our wholly-owned pipeline anticipated in 2019 IND filing for new wholly-owned program an
Read more →ANABAnaptysBio to Present at J.P. Morgan 37th Annual Healthcare Conference
SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of
Read more →ANABAnaptysBio Announces Third Quarter 2018 Financial Results and Provides Pipeline Updates
Reported positive top-line data from an interim analysis of its ongoing Phase 2a proof-of-concept clinical trial of etokimab in severe eosinophilic asthma Initiated Phase 2 ECLIPSE trial of etokimab in chronic rhinosinusitis with nasal polyps and Phase 2 POPLAR trial of ANB019 i
Read more →ANABAnaptysBio to Participate in Upcoming Investor Conferences
SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of
Read more →ANABAnaptysBio Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option
SAN DIEGO, Sept. 28, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced the closing of its underwritten public offer
Read more →ANABAnaptysBio Announces Pricing of Public Offering of Common Stock
AnaptysBio Announces Pricing of Public Offering of Common Stock SAN DIEGO, September 25, 2018 AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today annou
Read more →ANABAnaptysBio Reports Positive Topline Data from Phase 2a Proof-of-Concept Clinical Trial of Etokimab in Severe Eosinophilic Asthma Lung function improvement occurred rapidly following a single dose of etokimab, with an 8 p
AnaptysBio Reports Positive Topline Data from Phase 2a Proof-of-Concept Clinical Trial of Etokimab in Severe Eosinophilic Asthma SAN DIEGO, Sept. 24, 2018 AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidate
Read more →ANABAnaptysBio Announces Proposed Public Offering of Common Stock
SAN DIEGO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that it intends to offer $200.0 million of i
Read more →ANABAnaptysBio Announces Second Quarter 2018 Financial Results and Provides Pipeline Updates
Top-line Phase 2a Data from Etokimab (ANB020) in Eosinophilic Asthma Expected in Third Quarter of 2018 Etokimab Clinical Development Program Expanded to Include Chronic Rhinosinusitis with Nasal Polyps Commercial Considerations Led to Deprioritization of Further AnaptysBio-Spon
Read more →ANABAnaptysBio to Present at the 2018 Wedbush PacGrow Healthcare Conference
SAN DIEGO, Aug. 06, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of
Read more →ANABAnaptysBio to Present at the Jefferies 2018 Global Healthcare Conference
SAN DIEGO, May 30, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of An
Read more →ANABAnaptysBio Presents Updated ANB020 and ANB019 Clinical Data at the 2018 EAACI Congress
Blood eosinophil level reduction consistent with clinical efficacy in ANB020 Phase 2a atopic dermatitis trial ANB020-mediated eosinophil reduction is aligned with genotypic data from prior human IL-33 loss-of-function studies Favorable safety, pharmacokinetics and pharmacodynam
Read more →ANABAnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates
Positive Phase 2a Proof-of-Concept Data Reported from ANB020 Trials in Atopic Dermatitis Top-Line Phase 2a Data from ANB020 in Eosinophilic Asthma Expected in the Third Quarter of 2018 SAN DIEGO, May 08, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage
Read more →ANABAnaptysBio Announces ANB020 and ANB019 Clinical Data Presentations at the 2018 EAACI Congress
SAN DIEGO, May 01, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that clinical data for its ANB020 and ANB019 pr
Read more →ANABAnaptysBio To Participate in Upcoming Investor Conferences
SAN DIEGO, April 27, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that that company will participate in the fol
Read more →ANABAnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients 46% of adult peanut allergy patients with moderate-to-severe baseline symptoms tolerate
AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients March 26, 2018 AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates foc
Read more →ANABAnaptysBio Announces Fourth Quarter and Full Year 2017 Financial Results and 2018 Pipeline Milestones
ANB020 Top-Line Phase 2a Readouts Anticipated For Peanut Allergy in March 2018 and Eosinophilic Asthma in Second Quarter 2018 ANB019 GPP and PPP Phase 2 Studies to be Initiated During 2018 SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-
Read more →ANABAnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting
SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that updated data from the company’s Phase 2a
Read more →ANABAnaptysBio To Present Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting
SAN DIEGO, Feb. 07, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that data from the company’s Phase 2a trial of
Read more →ANABAnaptysBio Announces Presentation at the J.P. Morgan 36th Annual Healthcare Conference
SAN DIEGO, Jan. 02, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of A
Read more →ANABAnaptysBio Announces Third Quarter 2017 Financial Results and Provides Pipeline Updates
Announced Positive Proof-of-Concept Data for ANB020 in Atopic Dermatitis Announced Positive ANB019 Top-Line Phase 1 Trial Results Multiple Top-Line Clinical Data Readouts Expected Through the First Half of 2018 SAN DIEGO, Nov. 07, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nas
Read more →ANABAnaptysBio Reports Positive ANB019 Top-line Phase 1 Clinical Trial Results
Robust Half-Life and Extended Pharmacodynamic Activity Following a Single Dose of ANB019 Supports Advancement of ANB019 into Phase 2 Trials for IL-36-Associated Orphan Inflammatory Diseases SAN DIEGO, Nov. 06, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-
Read more →ANABAnaptysBio Announces Pricing of Public Offering
SAN DIEGO, Oct. 12, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced the pricing of its underwritten public offerin
Read more →ANABAnaptysBio Files Registration Statement for Proposed Public Offering
SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that it intends to offer and sell 3,000,000 sh
Read more →ANABAnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis
83 Percent of Patients Achieved EASI-50 at Day 29 Following a Single Dose of ANB020 EASI-50 was Observed Early and Persisted Through Day 57 Management to Host Conference Call Today at 8:30 a.m. EDT SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a
Read more →ANABANAPTYSBIO ANNOUNCES APPOINTMENT OF J. ANTHONY WARE, M.D. TO BOARD OF DIRECTORS SAN DIEGO , August 24 th , 2017 - AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody
ANAPTYSBIO ANNOUNCES APPOINTMENT OF J. ANTHONY WARE, M.D. TO BOARD OF DIRECTORS SAN DIEGO, August 24th, 2017 - AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflam
Read more →ANABAnaptysBio Announces Second Quarter 2017 Financial Results and Provides Pipeline Updates
Enrollment Completed in ANB020 Phase 2a Trial for Atopic Dermatitis Multiple Top-Line Clinical Data Readouts Expected in Second Half of 2017 SAN DIEGO, Aug. 10, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-c
Read more →ANABAnaptysBio to Present at Wedbush PacGrow Healthcare Conference
SAN DIEGO, Aug. 08, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, president and chief executiv
Read more →ANABANAPTYSBIO ANNOUNCES FIRST QUARTER 2017 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE Top-line Data from Ongoing ANB020 Phase 2a Trials and ANB019 Phase 1 Trial Expected in Second Half 2017
ANAPTYSBIO ANNOUNCES FIRST QUARTER 2017 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE Top-line Data from Ongoing ANB020 Phase 2a Trials and ANB019 Phase 1 Trial Expected in Second Half SAN DIEGO, May 11, 2017 - AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology co
Read more →ANABAnaptysBio Announces First-In-Human Dosing of ANB019
SAN DIEGO, April 06, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced first-in-human dosing of its wholly-owned pro
Read more →ANABAnaptysBio Announces 2016 Operating Results and Pipeline Progress Data from Ongoing ANB020 Phase 2a Trials and ANB019 Phase 1 Trial Expected in Second Half 2017
AnaptysBio Announces 2016 Operating Results and Pipeline Progress Data from Ongoing ANB020 Phase 2a Trials and ANB019 Phase 1 Trial Expected in Second Half 2017 SAN DIEGO, March 8, 2017 AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-
Read more →ANABAnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Presented at the AAAAI 2017 Annual Meeting
SAN DIEGO, March 04, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that its scientific collaborators at the Bena
Read more →ANABAnaptysBio to Present Data from ANB020 Program at Two Upcoming Medical Meetings
SAN DIEGO, Feb. 13, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that the company will present data from its AN
Read more →ANABAnaptysBio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, Jan. 31, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced the closing of its initial public offering of
Read more →ANABAnaptysBio Announces Pricing of Initial Public Offering
SAN DIEGO, Jan. 25, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced the pricing of its initial public offering of
Read more →Competitive Position
How ANAB ranks across every disease it competes inCompetitive Position is a premium feature
See how ANAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial